company background image
ALLK

Allakos NasdaqGS:ALLK Stock Report

Last Price

US$8.14

Market Cap

US$693.6m

7D

10.6%

1Y

-88.5%

Updated

05 Dec, 2022

Data

Company Financials +
ALLK fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALLK Stock Overview

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases.

Allakos Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Allakos
Historical stock prices
Current Share PriceUS$8.14
52 Week HighUS$86.95
52 Week LowUS$2.54
Beta0.51
1 Month Change35.89%
3 Month Change90.19%
1 Year Change-88.50%
3 Year Change-93.28%
5 Year Changen/a
Change since IPO-73.95%

Recent News & Updates

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Oct 18

Allakos prices ~$150M underwritten offering

Sep 19

Recent updates

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Aug 06
Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Apr 22
Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Dec 01
We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Aug 16
We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

May 02
We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

Mar 10
Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

Jan 28
Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

Dec 07
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

Shareholder Returns

ALLKUS BiotechsUS Market
7D10.6%4.2%1.5%
1Y-88.5%-7.4%-14.9%

Return vs Industry: ALLK underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: ALLK underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is ALLK's price volatile compared to industry and market?
ALLK volatility
ALLK Average Weekly Movement13.2%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: ALLK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ALLK's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012192Robert Alexanderhttps://www.allakos.com

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases.

Allakos Inc. Fundamentals Summary

How do Allakos's earnings and revenue compare to its market cap?
ALLK fundamental statistics
Market CapUS$693.56m
Earnings (TTM)-US$371.33m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALLK income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$371.33m
Earnings-US$371.33m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.36
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ALLK perform over the long term?

See historical performance and comparison